**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 56021

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Occurrence of seeding metastases in resectable perihilar cholangiocarcinoma and the role of low-dose radiotherapy to prevent this**

Franken LC *et al*. Preventive radiotherapy for PHC

Lotte C Franken, Eva Roos, Job Saris, Jeanin van Hooft, Otto van Delden, Joanne Verheij, Joris Erdmann, Marc G Besselink, Olivier R Busch, Geertjan van Tienhoven, Thomas M van Gulik

**Lotte C Franken, Eva Roos, Joris Erdmann, Marc G Besselink, Olivier R Busch, Thomas M van Gulik,** Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, Netherlands

**Job Saris, Jeanin van Hooft,** Department of Gastroenterology, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, Netherlands

**Otto van Delden,** Department of Interventional Radiology, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, Netherlands

**Joanne Verheij,** Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, Netherlands

**Geertjan van Tienhoven,** Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, Netherlands

**Author contributions:** Franken L, Saris J, van Gulik TM designed the research study; Franken LC, Saris J performed the research. Van Hooft J, Roos E, van Delden OM, Verheij J, Besselink MG, Erdmann JI, Busch OR, van Gulik TM contributed essential reagents or tools; Franken L, Saris J analyzed the data; Roos E, van Gulik TM, van Delden OM, Erdmann JI, Busch OR, van Gulik TM interpretation of data; Franken L, van Gulik TM, Roos E and van Gulik TM wrote the paper; Van Hooft J, Roos E, van Delden OM, Verheij J, Besselink MG, Erdmann JI, Busch OR and van Gulik TM revised work for important intellectual content.

**Corresponding author: Lotte C Franken, MD, Research Fellow,** Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, Netherlands. l.c.franken@amc.uva.nl

**Received:** April 13, 2020

**Revised:** August 11, 2020

**Accepted:** September 3, 2020

**Published online:**

**Abstract**

BACKGROUND

Preoperative biliary drainage in patients with presumed resectable perihilar cholangiocarcinoma (PHC) is hypothesized to promote the occurrence of seeding metastases. Seeding metastases can occur at the surgical scars or at the site of postoperative drains, and in case of percutaneous biliary drainage, at the catheter port-site. To prevent seeding metastases after resection, we routinely treated PHC patients with preoperative radiotherapy (RT) for over 25 years until January 2018.

AIM

To investigate the incidence of seeding metastases following resection of PHC.

METHODS

All patients who underwent resection for pathology proven PHC between January 2000 and March 2019 were included in this retrospective study. Between 2000-January 2018, patients received preoperative RT (3 × 3.5 Gray). RT was omitted in patients treated after January 2018.

RESULTS

A total of 171 patients underwent resection for PHC between January 2000 and March 2019. Of 171 patients undergoing resection, 111 patients (65%) were treated with preoperative RT. Intraoperative bile cytology showed no difference in the presence of viable tumor cells in bile of patients undergoing preoperative RT or not. Overall, two patients (1.2%) with seeding metastases were identified, both in the laparotomy scar and both after preoperative RT (one patient with endoscopic and the other with percutaneous and endoscopic biliary drainage).

CONCLUSION

The incidence of seeding metastases in patients with resected PHC in our series was low (1.2%). This low incidence and the inability of providing evidence that preoperative low-dose RT prevents seeding metastases, has led us to discontinue preoperative RT in patients with resectable PHC in our center.

**Key words:** Perihilar cholangiocarcinoma; Seeding metastases; Preventive radiotherapy

Franken LC, Roos E, Saris J, van Hooft J, van Delden O, Verheij J, Erdmann J, Besselink MG, Busch OR, van Tienhoven G, van Gulik TM. Occurrence of seeding metastases in resectable perihilar cholangiocarcinoma and the role of low-dose radiotherapy to prevent this. *World J Clin Cases* 2020; In press

**Core tip:** Routine preoperative radiotherapy (3 times 3.5 Gray) to prevent the occurrence of seeding metastases was used in our tertiary center for 28 years in patients undergoing resection for perihilar cholangiocarcinoma. Seeding metastases occurred in 2 out of 171 patients (1.2%) undergoing resection between 2000 and 2019. Intraoperative bile cytology showed no significant difference in the presence of tumor cells in the bile of patients undergoing preoperative radiotherapy or not. Due to the current low incidence of seeding metastases, preoperative radiotherapy to prevent seeding metastases is now abandoned in our institution.

**INTRODUCTION**

Patients with perihilar cholangiocarcinoma (PHC) have been treated with low-dose radiotherapy (RT) preoperatively at our institution since the early 90 s with the aim to prevent seeding metastases. Preoperative radiotherapy was introduced in our practice based on a study published by our institution in 1999, showing that 8 of 41 patients (20%) undergoing resection for PHC who were drained preoperatively, developed implantation metastases within 1 year after resection. In this study, endoscopic biliary drainage was performed in all 41 patients, combined with percutaneous biliary drainage in 4 of these patients. In addition, in 11 patients without biliary drainage, no seeding metastases were found[1]. It was hypothesized that biliary drainage, with perturbation of the tumor, enhances bile contamination with tumor cells, thereby increasing the risk of seeding metastases with bile spill incurred during resection.

In an effort to prevent this complication, all patients with resectable PHC at our tertiary center, received three times 3.5 Gray (Gy) external radiation therapy to the primary tumor on three consecutive days before surgery to kill free-floating tumor cells in the bile and destabilize the tumor cells that might be spilled during the operation. This concept of preventive, preoperative radiation therapy and dose regimen was based on a suggestion of a Mayo clinic study[2] and a study[3] in bladder carcinoma in which 3 times 3.5 Gy external radiation therapy had shown to be effective to reduce scar implementation metastases following surgery. Initial results of twenty-one patients with resected PHC who had undergone preoperative radiation, were promising with none of the patients developing seeding metastases[4].

Seeding metastases resulting from spill of bile during operation may become manifest in the tract of previous abdominal drains or laparotomy scar after resection. In addition, most patients with resectable PHC undergo preoperative biliary drainage which in itself, was thought to promote seeding metastases. Biliary drainage can be performed by two different approaches: Percutaneously or by the endoscopic route. Several studies have suggested that percutaneous biliary drainage carries an additional risk of developing seeding metastases along the catheter tract compared to endoscopic approaches, in which no catheter tract is created. Based on a described incidence of seeding metastases in the catheter tract after percutaneous biliary drainage of 2.6%-6.3%, several Asian authors[5-10] suggested that endoscopic biliary drainage should be the preferred approach.

The aim of this study was to update the occurrence of seeding metastases in our institution and evaluate the role of preventive pre-operative low-dose radiotherapy in patients with resectable PHC.

**MATERIALS AND METHODS**

All consecutive patients who underwent resection for pathology proven perihilar cholangiocarcinoma at the Amsterdam UMC (location Academic Madical Center) between January 2000 and March 2019 were included in this retrospective study. The need for ethical approval was waived by the Medical Ethics Review Committee of the Amsterdam UMC (W19\_155).

Whereas patients with intraductal papillary neoplasm of the bile duct were included in this analysis, patients with other final pathology diagnosis were excluded. Patient and tumor characteristics were obtained from a prospectively maintained database including all patients undergoing resection under the suspicion of PHC. Data regarding preoperative work-up, biliary drainage, radiotherapy, type of surgery, postoperative course, follow-up and recurrence was collected. Jaundiced patients were treated by endoscopic biliary drainage or percutaneous biliary drainage, or a combination of both, with a preference at our institution for initial endoscopic biliary drainage.

Patients were stratified according to type of biliary drainage, while patients undergoing both percutaneous and endoscopic biliary drainage were analysed as a separate group. Surgical procedures generally consisted of resection of the extrahepatic bile duct in combination with (extended) hemihepatectomy. After 2009, intra-operative bile sampling for cytology was routinely performed in the majority of the patients. Results of bile cytology were compared between patients undergoing preoperative radiotherapy or not. Standard follow up after resection was 5 years. Imaging was not standard incorporated in oncological follow-up, but performed when patients showed symptoms of recurrent disease.

Between 2000 and January 2018, patients undergoing resection for perihilar cholangiocarcinoma were irradiated to 3 times 3.5 Gy to the tumor in the liver hilum, administered on three consecutive days prior to resection. Up to 2004, the hilar area was identified using a conventional simulator, based on the position of the biliary stents. From 2004 onwards, computerized tomography based planning was used. Throughout, a 3D conformal technique was applied. Patients treated between 2000 and 2012, were also included in the study by Wiggers *et al*[11] Primary outcome of this study was the occurrence of seeding metastases, defined as metastases occurring in the laparotomy scar or in tracts of previous abdominal drains. Recurrence was defined as radiologically suspected or pathologically proven recurrence and time of recurrence was documented. Peritoneal recurrence, unlike in other studies, was also not considered as seeding metastases. Only the initial location of recurrence was registered.

***Statistical analyses***

Descriptive statistics were used to describe the data using statistical product and service solutions version 25 (International Business Machines Corporation, Armonk, NY, United States). The Chi-square test was used to compare the incidence of seeding metastases and the occurrence of tumor cells in bile cytology between groups. Duration of drainage was compared using Mann-Witney *U* test.

**RESULTS**

A total of 171 patients who underwent resection for pathology proven PHC between 2000 and March 2019 were identified (Table 1). The median follow-up of survivors was 36 mo [interquartile range (IQR): 16-81]. Biliary drainage prior to resection was performed in 145 patients (85%). In 81 (56%) patients endoscopic biliary drainage took place, 14 (10%) patients underwent percutaneous biliary drainage and 50 (34%) patients underwent both drainage routes, due to the absence of therapeutic success of one route. Median duration between (first) biliary drainage and surgery was 76 d (IQR: 53-101 d) for endoscopic drainage, 53 d (IQR: 36-80 d) for percutaneous biliary drainage and 76 d (range 61-99 d) for both endoscopic and percutaneous biliary drainage, respectively (*P* = 0.026). Of these 171 patients, there were 161 patients treated between January 2000-January 2018 and ten patients treated between February 2018 and March 2019.

***Radiotherapy***

A total of 111 patients (65%) underwent preoperative radiotherapy (3 times 3.5 Gy) to reduce the risk of seeding metastases (Figure 1). As part of another study[12], 13 patients were additionally treated with postoperative radiotherapy (as well as preoperative radiotherapy) between 2000 and 2001 (20 × 2.2 Gy).

***Intraoperative bile cytology***

After 2009, intraoperative bile cytology was obtained in 76 of 125 patients (61%). Bile cytology showed (suspicion of) tumor cells in 24 of 76 patients (32%) and was negative in 33 of 76 patients (45%). In the remaining patients, bile cytology was inconclusive in 9 (12%) and not assessable in 10 of 76 patients (14%). Malignant cells were found in the conclusive bile samples of 18 of 41 patients (44%) treated with radiotherapy and in 6 of 16 (37%) patients not treated with radiotherapy. No difference in the distribution of positive or negative bile cytology was observed between patients who were treated with preoperative radiotherapy or not (*P* = 0.660).

***Seeding metastases***

Two patients with metastases in the laparotomy scar (1.2%) were identified (Figure 1). Both patients had been treated with preoperative radiotherapy and one patient was additionally treated with postoperative radiotherapy. Histopathology showed moderately differentiated adenocarcinoma in both cases and both resections were R1 resections. The seeding metastases occurred 21 and 17 mo after resection, respectively. Overall, the incidence of seeding metastases was 1.4% (1 of 81 patients) after endoscopic biliary drainage, 2% (1 of 50 patients) after combined endoscopic and percutaneous biliary drainage, and 0% after both percutaneous biliary drainage (14 patients) and no biliary drainage (26 patients) (*P* = 0.852).

**DISCUSSION**

The hypothesis underlying this study was that low-dose preoperative radiotherapy eradicates free-floating vital tumor cells in bile, thereby reducing the risk of seeding metastases incurred during bile spill at the time of resection. The outcome of this study including 171 patients who had undergone resection for PHC, was that only two patients (1.2%) developed seeding metastases (both at the laparotomy scar). Intraoperative bile cytology showed no significant difference in the presence of tumor cells in bile of patients who underwent preoperative radiotherapy or not.

To our knowledge, literature on application of preoperative radiotherapy in patients with resectable PHC from other centers is lacking. As mentioned above, preoperative radiotherapy was introduced at our institution based on a 20% incidence of seeding metastases reported back in 1999 that has shown a striking decrease to currently 1.2%, suggesting a positive effect of preoperative radiotherapy. However, Wiggers *et al*[11] published a combined analysis of 234 patients from our institution (academic medical center, amsterdam and memorial sloan kettering cancer center, New York)[11]. This study included 106 patients from the academic medical center who were subjected to preoperative RT and 128 patients from amsterdam and memorial sloan kettering cancer center were no preoperative RT is given, the difference in the percentage of seeding metastases between both centers (2 of 106; 1.9% *vs* 5 of 128; 3.9% *P* = 0.46) was not significant and the overall incidence was low (3.0%)[11]. Therefore, evidence of a potential benefit of low dose preoperative radiation cannot be delivered, since this would require a randomized study with approximately 1200 patients per arm, which is not feasible for such a rare disease. In view of the incidence of local and distant recurrences and the overall prognosis of PHC, the overall incidence of seeding metastases is clinically less relevant. Hence, in January 2018 we decided to discontinue low dose preoperative radiotherapy. Interestingly, the potential of treatment with stereotactic body radiation therapy for patients with unresectable perihilar cholangiocarcinoma is currently being investigated by multiple group[13,14].

The concept of 3 times 3.5 Gy preoperative radiation therapy to reduce the risk of seeding metastases was based on a study in bladder carcinoma first published in 1969[15]. Follow-up studies on the effect of preoperative low-dose radiotherapy in bladder carcinoma however, are lacking while low-dose radiotherapy seems to have been abandoned in these patients.

In current literature, indeed, a trend of a lower seeding metastases rate is observed (Table 2)[5-10,16]. For example, incidence reported by investigators from Hokkaido University Hospital decreased from 6.3% (3 of 48)[5] to 4.5% (3 of 67)[16] in their publications from 2011 and 2014, respectively. Likewise in Nagoya University Hospital, catheter tract recurrence was reported to be 5.6% (19 of 339) in a study performed by Kim *et al*[10]. In 2015[10], whilst this decreased to 3.6% (6 of 168) in a study published in 2017[6]. Surgical techniques for resection of PHC have been refined reducing bile spill, which may have contributed to this decrease.

Our reported incidence of 1.2%, based one of the largest series on this topic, remains lower than the incidence reported in other studies (up to 6.3%)[5-10,16]. Several factors may contribute to the development of seeding metastases. As mentioned above, preoperative biliary drainage is thought to increase the risk of seeding metastases by enhancing bile contamination with tumor cells. There are some drainage related factors that potentially influence the development of seeding metastases, one of them being the duration of biliary drainage. A recently published study by Komaya *et al*[6], including 341 resected PHC patients, did not describe the duration of biliary drainage in their patients, although in another study originating from the same group, duration of percutaneous biliary drainage of 60 d or more was identified as an independent risk factor for the development of catheter tract recurrence in distal and perihilar cholangiocarcinoma[7]. In other studies reporting on seeding metastases, duration of biliary drainage was often not reported. In our series, the median duration of biliary drainage of 73 d after endoscopic biliary drainage and 77 d after percutaneous biliary drainage would suggest an increased risk in the majority of our patients, but the overall incidence was low (1.2%). Therefore, we cannot fully exclude the possibility that there was an effect of preoperative radiotherapy based on this series alone.

Related to biliary drainage, the type (endoscopic or percutaneous), placement (proximal or transtumoral) may also play a role. Komaya *et al*[6] showed that the incidence of seeding metastases was higher after percutaneous biliary drainage (44 of 165, 26.7%) compared to endoscopic biliary drainage (25 of 150, 16.7%). Their definition of seeding metastases included right-sided pleural dissemination as well as peritoneal dissemination and catheter tract recurrences, due to the use of the transpleural approach of percutaneous biliary drainage in this cohort, resulting in relatively high seeding metastases rates. Separate analysis of catheter tract recurrence, showed occurrence of catheter tract recurrence in 6 of 164 patients (3.7%) undergoing percutaneous drainage while recurrence at the laparotomy scar was not described[6]. In contrary, the previously mentioned study by Wiggers including 234 patients showed no significant difference in the occurrence of seeding metastasis between different drainage approaches: 3.4% after percutaneous and 2.7% after endoscopic biliary drainage (*P* = 0.71)[11].

**conclusion**

This study has several limitations, the main limitation being the retrospective design of this single-center study, introducing a significant risk of bias. A direct comparison between patients undergoing preoperative radiation to those who did not is not possible within this study. Before January 2018, patients who did not undergo preoperative radiotherapy (35%) were not randomly assigned and most likely there was a reason not to treat them with preoperative radiotherapy (for example because they did not undergo biliary drainage or for logistic reasons). For some patients treated after stopping preoperative RT in January 2018, follow-up might be too short for seeding metastases to develop, as seeding metastases occurred after a median of 17 mo in the study by Wiggers *et al*[11]. In addition, due to the absence of standardized follow-up imaging after resection, not all seeding metastases or recurrences may have been detected. When comparing cytology results of patients with and without radiotherapy, we could not account for viability of the cells. Although cells may stain positively, this does not mean that these cells are still viable and therefore, we could have overlooked an effect of radiotherapy. Due to the overall low number of events (seeding metastases), proper statistical analysis was not feasible in this series and confidence limits are huge.

The incidence of seeding metastases in patients with resected PHC has decreased and is currently low (1.2% in our institution). As the only center in the world reporting on preventive low-dose RT, we were unable to deliver evidence of a potential benefit of preoperative radiotherapy and therefore preoperative radiotherapy in patients with resectable PHC has been discontinued in our institution.

**ARTICLE HIGHLIGHTS**

***Research background***

Routine preoperative radiotherapy (3 times 3.5 Gray) to prevent the occurrence of seeding metastases was used in our tertiary center for 28 years in patients undergoing resection for perihilar cholangiocarcinoma.

***Research motivation***

Previous research from our department showed that seeding metastases occurred in up to 20% of the patients undergoing resection of perihilar cholangiocarcinoma.

***Research objectives***

To investigate the occurrence of seeding metastases among patients with resectable perihilar cholangiocarcinoma.

***Research methods***

A retrospective study was conducted, including all patients undergoing resection of perihilar cholangiocarcinoma in a larger tertiary center between 2000 and March 2019.

***Research results***

Seeding metastases occurred in 2/171 (1.2%) of the patients undergoing resection for perihilar cholangiocarcinoma**.** These seeding metastases occurred at the laparotomy scar in both patients, after 17 and 21 mo, respectively**.** Intraoperative bile cytology showed no significant difference in the presence of tumor cells in the bile of patients undergoing preoperative radiotherapy or not.

***Research conclusions***

The incidence of seeding metastases in patients with resected perihilar cholangiocarcinoma has decreased. Evidence of a potential benefit of preoperative radiotherapy could not be delivered and therefore preoperative radiotherapy in patients with resectable perihilar cholangiocarcinoma has been discontinued in our institution.

***Research perspectives***

As we are the only center reporting on the use of low-dose radiotherapy to prevent seeding metastases, it is unlikely that other reports on this topic will appear and future research may focus more on the potential of stereotactic body radiation therapy to treat patients with unresectable perihilar cholangiocarcinoma.

**REFERENCES**

1 **ten Hoopen-Neumann H**, Gerhards MF, van Gulik TM, Bosma A, Verbeek PC, Gouma DJ. Occurrence of implantation metastases after resection of Klatskin tumors. *Dig Surg* 1999; **16**: 209-213 [PMID: 10436369 DOI: 10.1159/000018729]

2 **Buskirk SJ**, Gunderson LL, Schild SE, Bender CE, Williams HJ Jr, McIlrath DC, Robinow JS, Tremaine WJ, Martin JK Jr. Analysis of failure after curative irradiation of extrahepatic bile duct carcinoma. *Ann Surg* 1992; **215**: 125-131 [PMID: 1312319 DOI: 10.1097/00000658-199202000-00006]

3 **van der Werf-Messing BH**. Cancer of the urinary bladder treated by interstitial radium implant. *Int J Radiat Oncol Biol Phys* 1978; **4**: 373-378 [PMID: 689940 DOI: 10.1016/0360-3016(78)90065-2]

4 **Gerhards MF**, Gonzalez DG, ten Hoopen-Neumann H, van Gulik TM, de Wit LT, Gouma DJ. Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy. *Eur J Surg Oncol* 2000; **26**: 480-485 [PMID: 11016470 DOI: 10.1053/ejso.1999.0926]

5 **Kawakami H**, Kuwatani M, Onodera M, Haba S, Eto K, Ehira N, Yamato H, Kudo T, Tanaka E, Hirano S, Kondo S, Asaka M. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. *J Gastroenterol* 2011; **46**: 242-248 [PMID: 20700608 DOI: 10.1007/s00535-010-0298-1]

6 **Komaya K**, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: A propensity score matching analysis of resectable perihilar cholangiocarcinoma. *Surgery* 2017; **161**: 394-404 [PMID: 27712872 DOI: 10.1016/j.surg.2016.08.008]

7 **Takahashi Y**, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. *Br J Surg* 2010; **97**: 1860-1866 [PMID: 20799295 DOI: 10.1002/bjs.7228]

8 **Sakata J**, Shirai Y, Wakai T, Nomura T, Sakata E, Hatakeyama K. Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma. *World J Gastroenterol* 2005; **11**: 7024-7027 [PMID: 16437610 DOI: 10.3748/wjg.v11.i44.7024]

9 **Kang MJ**, Choi YS, Jang JY, Han IW, Kim SW. Catheter tract recurrence after percutaneous biliary drainage for hilar cholangiocarcinoma. *World J Surg* 2013; **37**: 437-442 [PMID: 23188530 DOI: 10.1007/s00268-012-1844-1]

10 **Kim KM**, Park JW, Lee JK, Lee KH, Lee KT, Shim SG. A Comparison of Preoperative Biliary Drainage Methods for Perihilar Cholangiocarcinoma: Endoscopic *vs* Percutaneous Transhepatic Biliary Drainage. *Gut Liver* 2015; **9**: 791-799 [PMID: 26087784 DOI: 10.5009/gnl14243]

11 **Wiggers JK**, Groot Koerkamp B, Coelen RJ, Doussot A, van Dieren S, Rauws EA, Schattner MA, van Lienden KP, Brown KT, Besselink MG, van Tienhoven G, Allen PJ, Busch OR, D'Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, Verheij J, Jarnagin WR, van Gulik TM. Percutaneous Preoperative Biliary Drainage for Resectable Perihilar Cholangiocarcinoma: No Association with Survival and No Increase in Seeding Metastases. *Ann Surg Oncol* 2015; **22 Suppl 3**: S1156-S1163 [PMID: 26122370 DOI: 10.1245/s10434-015-4676-z]

12 **Gerhards MF**, van Gulik TM, González González D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. *World J Surg* 2003; **27**: 173-179 [PMID: 12616432 DOI: 10.1007/s00268-002-6434-1]

13 **Kozak MM**, Toesca DAS, von Eyben R, Pollom EL, Chang DT. Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control with Elective Nodal Irradiation. *Adv Radiat Oncol* 2020; **5**: 77-84 [PMID: 32051893 DOI: 10.1016/j.adro.2019.08.003]

14 **Koedijk MS**, Heijmen BJM, Groot Koerkamp B, Eskens FALM, Sprengers D, Poley JW, van Gent DC, van der Laan LJW, van der Holt B, Willemssen FEJA, Méndez Romero A. Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study. *BMJ Open* 2018; **8**: e020731 [PMID: 30327398 DOI: 10.1136/bmjopen-2017-020731]

15 **van der Werf-Messing B**. Carcinoma of the bladder treated by suprapubic radium implants. The value of additional external irradiation. *Eur J Cancer* 1969; **5**: 277-285 [PMID: 4977652 DOI: 10.1016/0014-2964(69)90078-4]

16 **Hirano S**, Tanaka E, Tsuchikawa T, Matsumoto J, Kawakami H, Nakamura T, Kurashima Y, Ebihara Y, Shichinohe T. Oncological benefit of preoperative endoscopic biliary drainage in patients with hilar cholangiocarcinoma. *J Hepatobiliary Pancreat Sci* 2014; **21**: 533-540 [PMID: 24464984 DOI: 10.1002/jhbp.76]

**Footnotes**

**Institutional review board statement:** The need for ethical approval was waived by the Medical Ethics Review Committee of the Amsterdam UMC (W19\_155).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** April 13, 2020

**First decision:** June 18, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Netherlands

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Coco D, Sperti C **S-Editor:** Zhang L **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Flowchart of patients with perihilar cholangiocarcinoma.**

 **Table 1 Characteristics of patients undergoing resection for perihilar cholangiocarcinoma**

|  |  |
| --- | --- |
| **Characteristics** | **Patients with PHC (*n* = 171)** |
| Age, mean (SD) | 64 (10) |
| Male, *n* (%) | 104 (63) |
| ASA, *n* (%) |  |
|  1 | 30 (18) |
|  2 | 112 (66) |
|  3 | 27 (16) |
| Missing | 2 (1) |
| Drainage, *n (%)* |  |
| None | 26 (15) |
| Endoscopic biliary drainage | 81 (47) |
| Percunatenous biliary drainage | 14 (8) |
| Both | 50 (29) |
| Bismuth-Corlette type, *n (%)* |  |
| I | 4 (2) |
| II | 12 (7) |
|  IIIa | 85 (51) |
|  IIIb | 42 (25) |
| IV | 24 (14) |
| Missing | 4 (3) |
| Portal vein embolization, *n (%)* | 20 (12) |
| Radiotherapy*, n (%)* | 111 (65) |
| Resection type, *n (%)* |  |
| Left hemihepatectomy | 61 (36) |
| Extended left hemihepatectomy | 6 (4) |
| Right hemihepatectomy | 39 (23) |
| Extended right hemihepatectomy | 46 (28) |
| Minor liver resection | 4 (2) |
| External bile duct resection only | 13 (8) |
| + pancreatoduodenectomy | 4 (2) |
| + Portal vein reconstruction | 43 (26) |
| 90-d mortality, *n (%)* | 22 (13) |
| 90-d morbidity, *n (%)* | 126 (74) |
| Severe morbidity (Clavien-Dindo ≥ 3), *n (%)* | 96 (56) |
| Recurrence, *n (%)* | 61 (36) |
| Local recurrence | 37 (22) |
| Liver metastases | 10 (6) |
| Lung metastases  | 2 (1) |
| Peritoneal metastases | 7 (4) |
| Other | 5 (3) |

SD: Standard deviation; ASA: American society of anesthesiologists.

**Table 2 Overview of studies reporting on incidence of seeding metastases in patients with perihilar cholangiocarcinoma**

|  |  |  |
| --- | --- | --- |
|  | **Incidence** | **Patients**  |
| Sakata *et al*[8], 2005 | 3/67 (4.4%), cumulative 6% | Niigata University Graduate School of Medical and Dental Sciences; Percutaneous biliary drainage, 1998-2002 |
| Kang *et al*[9], 2013 | 6/232 (2.6%) + 8 abdominal wall/wound implant metastases (3.4%)  | Seoul National University Hospital; Percutaneous biliary drainage, 1991-2011 |
| Kim *et al*[10], 2015 | 2/52 (3.8%) | Samsung Medical Center Seoul; Percutaneous biliary drainage, 2000-2012 |
| Kawakami *et al*[5], 2011 | 3/48 (6.3%)  | Hokkaido University Hospital; Percutaneous biliary drainage, 1999-2009 |
| Hirano *et al*[16], 2014 | 3/67 (4.5%) | Hokkaido University hospital; Percutaneous biliary drainage, 2000-2008 |
| Takahashi *et al*[7], 2010 | 19/339 (5.6%) | Nagoya University hospital, 1977-2007 |
| Komaya *et al*[6], 2017 | 6/168 (3.6%) | Nagoya University Hospital Percutaneous biliary drainage, 2003-2012 |
| Ten Hoopen *et al*[1], 1999  | 8/41 (20%) | AMC Amsterdam; Biliary drainage, 1983-1990 |
| Wiggers *et al*[11], 2013 | 2/106 (1.9%) | AMC Amsterdam; Percutaenous + endoscopic biliary drainage, 1991-2012 |